



## STEP THERAPY POLICY

- POLICY:** Alzheimer's Disease Step Therapy Policy
- Adlarity® (donepezil transdermal system – Corium)
  - Aricept®, Aricept® ODT (donepezil tablets and orally disintegrating tablets – Pfizer/Eisai, generic)
  - Exelon® (rivastigmine capsules – Novartis, generic)
  - Exelon® Patch (rivastigmine transdermal system – Novartis, generic)
  - Namzaric® (memantine and donepezil hydrochlorides extended-release capsules – Forest, generic)
  - Razadyne® (galantamine tablets and oral solution – Janssen, generic)
  - Razadyne® ER (galantamine extended-release capsules – Janssen, generic)
  - Zunveyl (benzgalantamine delayed-release tablets – Alpha Cognition)

**REVIEW DATE:** 12/04/2024; selected revision 02/05/2025 and 04/23/2025

---

### INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## CIGNA NATIONAL FORMULARY COVERAGE:

### OVERVIEW

The acetylcholinesterase inhibitors (ChIs) [donepezil, rivastigmine, galantamine, benzgalantamine] and the *N*-methyl-D-aspartate (NMDA) antagonist memantine are indicated for the **treatment of Alzheimer's disease (AD)**.<sup>1-9</sup>

- Adlarity, donepezil, and transdermal rivastigmine are the only agents approved for **all degrees of AD [mild, moderate, and severe]**.
- Benzgalantamine, galantamine/galantamine extended-release (ER) and oral rivastigmine are approved for **mild to moderate AD**.
- Oral and transdermal rivastigmine are also indicated for the **treatment of mild to moderate dementia associated with Parkinson's disease (PD)**.
- Memantine/donepezil ER capsules are indicated for the **treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on donepezil 10 mg once daily**.

Memantine ER/donepezil capsules are a fixed-dose combination containing donepezil and memantine ER.<sup>8</sup>

## **POLICY STATEMENT**

This program has been developed to encourage the use of a Step 1 (A or B) Product prior to the use of a Step 2 (A or B) Product. If the Step Therapy rule is not met for the Step 2 (A or B) Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

Note: This program has two separate components: one for **generic acetylcholinesterase inhibitor products** (does NOT include donepezil 23 mg tablets) and one for the **Aricept 23 mg strength products (brand or generic)**. This policy does not include the single-agent NMDA antagonists.

### **Generic acetylcholinesterase inhibitor:**

**Step 1A:** generic donepezil tablets and orally disintegrating tablets (does NOT include donepezil 23 mg tablets), generic galantamine tablets or oral solution, generic galantamine extended-release capsules, generic rivastigmine capsules, generic rivastigmine transdermal system

**Step 2A:** Adlarity, Aricept 5 and 10 mg tablets, Aricept ODT, Exelon, Exelon Patch, Namzaric (brand or generic), Razadyne, Razadyne ER, Zunveyl

### **Aricept 23 mg strength (brand or generic):**

**Step 1B:** Aricept 10 mg tablets (brand or generic), Aricept ODT 10 mg (brand or generic)

**Step 2B:** Aricept 23 mg tablets (brand or generic)

**Alzheimer's Disease Step Therapy Policy product(s) is(are) covered as medically necessary when the following step therapy criteria is(are) met. Any other exception is considered not medically necessary.**

## **CRITERIA**

### **Generic acetylcholinesterase inhibitor criteria**

1. If the patient has tried one Step 1A Product, approve a Step 2A Product.

### **Aricept 23 mg strength (brand or generic) criteria**

1. If the patient has tried one Step 1B Product, approve a Step 2B Product.

## **REFERENCES**

1. Aricept® tablets/Aricept® ODT (orally disintegrating tablets) [prescribing information]. Woodcliff Lake, NJ: Eisai; December 2018.
2. Razadyne® tablets [prescribing information]. Titusville, NJ: Janssen; August 2021.
3. Razadyne® ER extended-release capsules [prescribing information]. Titusville, NJ: Janssen; September 2022.
4. Exelon® capsules [prescribing information]. East Hanover, NJ: Novartis; December 2018.
5. Exelon® patch [prescribing information]. East Hanover, NJ: Novartis; May 2024.
6. Namenda® tablets and oral solution [prescribing information]. Madison, NJ: Allergan; November 2018.
7. Namenda XR® extended-release capsules [prescribing information]. Madison, NJ: Allergan; November 2019.
8. Namzaric® extended-release capsules [prescribing information]. Madison, NJ: Allergan; July 2019.
9. Adlarity® transdermal system [prescribing information]. Grand Rapids, MI: Corium; March 2022.
10. Zunveyl delayed-release tablets [prescribing information]. Grapevine, TX: Alpha Cognition; July 2024.

## **HISTORY**

<b>Type of Revision</b>	<b>Summary of Changes</b>	<b>Review Date</b>
Annual Revision	No criteria changes.	12/06/2023
Annual Revision	No criteria changes.	12/04/2024
Selected Revision	<b>Generic memantine and donepezil hydrochlorides extended-release capsules:</b> Generic to Namzaric added to Step 2A Products.	02/05/2025
Selected Revision	<b>Zunveyl:</b> Zunveyl was added to Step 2A Products.	04/23/2025

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.